Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.

Life (Basel) · 2022 · PMC9504973 · PMID 36143391

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this study, both olaparib and niraparib showed a trend toward more reported hematologic AEs than other AEs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.